GPT and metabolic dysfunction-associated steatotic liver disease: Twelve RCTs (six testing efficacy of dapagliflozin, three RCTs on EMPA, two RCTs testing ipragliflozin, and one RCT on canagliflozin). The drugs were to treat obese, middle-aged individuals with NAFLD. It was found that the drug decreased the amount of serum alanine aminotransferase, γ-glutamyl transferase, and the liver fat content percentage examined by magnetic resonance-based techniques.